The worldwide biologics market is anticipated to reach nearly USD 400 billion by 2025. It was estimated at USD 276.6 billion in 2015. Widespread adoption of customized medicines and introduction of targeted therapies is expected to spur market demand. Furthermore, growing significance of biologics can lead to higher market revenues over the forecast period.
Biologics are medicines derived from living cells to treat chronic diseases like cancer. They are used in traditional research, therapeutics, reagents, monoclonal antibodies (mAbs), and other medicines. They are also known as biopharmaceuticals. Majority of these are produced using recombinant DNA technology. This technology allows a company to produce customized medicines to treat specific diseases. Alternatives to biologics are biobetters and biosimilars.
Biosimilars are biologics manufactured by a different company. They are also known as follow-on biologics (FOB) and subsequent entry biologics (SEB). Biobetters are recombinant drugs, which are considered the refined versions of biopharmaceuticals. These receive 12 years of market protection as against biosimilars. Thus, a number of companies have begun investing in these due to the near patent expiry of biopharmaceuticals like Herceptin (trastuzumab).
In-depth research report on global biologics market - http://www.grandviewresearch.com/industry-analysis/biologics-market
The global biologics market is fragmented according to sources, products, manufacturing, disease categories, and regions. Sources include mammalian, microbial, and others. ‘Others’ includes insect, avian, and transgenic animals. Microbial systems have been leading the global market in recent years on account of drugs manufactured via this system. These rely on Escherichia coli and yeast. Recombinant proteins, granulocyte colony-stimulating factor (G-CSF), and recombinant insulin are products derived from this system.
On the basis of products, the market is divided into antisense, molecular therapy, and RNAi, mAbs, recombinant proteins, vaccines, and others. Due to wide application scope, mAbs have been dominating the market in recent years in terms of revenue. These drugs are used in treating autoimmune diseases and various types of cancers. Vaccines are expected to grow robustly in the forthcoming years due to their disease preventing roles. Development of a virus-based vaccine for treating melanoma can benefit this segment.
Biopharmaceuticals are manufactured in two ways, namely in-house and outsourcing. In-house manufacturing is preferred by major companies because this helps them enhance their bioprocessing capabilities. Outsourcing is expected to experience sluggish growth over the forecast period. Disease categories in the biologics market are infectious diseases, immunological disorders, hematological disorders, cardiovascular disorders, oncology, and others. Oncology has been leading the global market over the recent decade and is expected to retain its dominant position in the forthcoming years as well. Introduction of novel biopharmaceuticals to combat various cancers is expected to spur growth of this segment.
Major geographical segments of the overall market are North America, Latin America, Middle East and Africa (MEA), Asia Pacific (APAC), and Europe. North America dominates the biopharmaceuticals market in terms of revenue. It is driven by presence of established players in the region and high demand for biologics to treat diseases. The APAC market is expected to display significant growth over the forecast period. Presence of companies like Wu Xi Biologics is expected to contribute to regional demand.
Key market players are AbbVie Inc.; Pfizer Inc.; Merck & Co. Inc.; Amgen Inc.; and Eli Lilly & Company. These players invest in hybrid business models that make use of novel technologies and platforms. Development of better delivery models may enable them to retain their competitiveness amid the manufacturers of biosimilars and biobetters. For instance, Pfizer has decided to expand its R&D by investing in startups. It may extend aid to 4D Molecular Therapeutics, Inc. to encourage the production of vectors to target certain cardio-related disorders.